engleski

Pharmacotherapy of Alzheimer Dementia

Dementia is characterised with multiple cognitive deficits which include memory impairement. It is the most common in the elderly . Present guidelines for pharmacotherapy of Alzheimer Dementia, based on our clinical experience and data from scientific and clinical research have been described. Presently, inhibitors of acetylcholinesterase are used in the treatment of AD. Most common side effects in therapy with inhibitors of acetilcholinesteraze are gastrointestinal side effects, tiuredness, headeche and dizzines. Agressiviness and agitation are present in 80% of patients suffering from AD. Benzodiazepines, mood stabilizers and antipsychotics are approved in these cases. The prevalence of depressive simptoms in patients with AD is 25-30%. Treatment with antidepressants is indicated in these cases with selective serotonin reuptake inhibitors being the first line of treament. Beside clinical examination, taking hetheroanamnesis obtained form the members of the family and caregivers into consideration is crucial. Neuropsychological estimation, as well as the scales of general clinical estimation are considered to be good indicators for efficacy of the therapy.

pharmacotherapy; Alzheimer dementia

nije evidentirano